Diabetes | pharmaphorum

Skip to main content

Saturday 4 April 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Diabetes

News

Capitol Hill

Senate could back Trump health law by 4th July, despite warn...

Reforms could take away health insurance from 23 million, and deny insurance to those with pre-existing conditions, such as diabetes

News

medtronic-hq

A milestone in insulin automation, Medtronic's MiniMed 670G ...

The MiniMed 670G has launched in the US, following FDA approval last year.

Views & Analysis

Financial center of Panama City, Panama

ADA preview: cardio data in diabetes, drug costs and healthc...

Invokana data could suggest cardio benefit for SGLT2 class.

Views & Analysis

Novo Nordisk HQ flag hires

Novo Nordisk: survival of the fittest applies in diabetes an...

Diabetes specialist Novo Nordisk is feeling the heat from increasingly price conscious US payers.

News

glooko

Glooko and Dexcom expand diabetes deal

Deal will let patients access diabetes data in real-time.

News

Novo Nordisk HQ flag hires

Novo hopes hypoglycaemia data will boost Tresiba

Lower severe hypo risk compared with Lantus - but no cardiac benefit.

Load more results

Editor's Picks

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

US court says pharma giants must face False Claims suit

Meningitis outbreak in UK prompts call to widen vaccination

US judge rules Kennedy's vaccine changes 'unlawful'

Generic semaglutide in India, and other weight-loss news

Sales & Marketing

Interview with Craig Ackerman Reuters at Pharma USA 2026

Biotech is back, with Craig Ackerman

In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights further

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company